Back DJ - Search Results

1

Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.

Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back DJ, Khoo S. Marzolini C, et al. Among authors: back dj. Clin Pharmacol Ther. 2022 Dec;112(6):1191-1200. doi: 10.1002/cpt.2646. Epub 2022 Jun 7. Clin Pharmacol Ther. 2022. PMID: 35567754 Free PMC article. Review.

2

Improved tolerability of ritonavir derived from pharmacokinetic principles.

Merry C, Barry M, Gibbons S, Mulcahy F, Back D. Merry C, et al. Br J Clin Pharmacol. 1996 Dec;42(6):787. doi: 10.1046/j.1365-2125.1996.d01-3339.x. Br J Clin Pharmacol. 1996. PMID: 8971438 Free PMC article. Clinical Trial. No abstract available.

3

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.

Barry M, Gibbons S, Back D, Mulcahy F. Barry M, et al. Clin Pharmacokinet. 1997 Mar;32(3):194-209. doi: 10.2165/00003088-199732030-00003. Clin Pharmacokinet. 1997. PMID: 9084959 Review.

4

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.

Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Barry M, et al. Clin Pharmacokinet. 1999 Apr;36(4):289-304. doi: 10.2165/00003088-199936040-00004. Clin Pharmacokinet. 1999. PMID: 10320951 Review.

5

Current uses and future hopes for clinical pharmacology in the management of HIV infection.

Back D, Khoo S, Maher B, Gibbons S. Back D, et al. HIV Med. 2000 Jul;1 Suppl 2:12-7. doi: 10.1046/j.1468-1293.2000.00001.x. HIV Med. 2000. PMID: 11737367 Free article. Review. No abstract available.

6

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.

Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A; Swiss HIV Cohort Study. Fellay J, et al. Among authors: back dj. Lancet. 2002 Jan 5;359(9300):30-6. doi: 10.1016/S0140-6736(02)07276-8. Lancet. 2002. PMID: 11809184

7

Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment.

Boffito M, Rossati A, Reynolds HE, Hoggard PG, Back DJ, Di Perri G. Boffito M, et al. Among authors: back dj. AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):341-2. doi: 10.1089/088922202753519115. AIDS Res Hum Retroviruses. 2002. PMID: 11897035 No abstract available.

8

The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.

Boffito M, Hoggard PG, Reynolds HE, Bonora S, Meaden ER, Sinicco A, Di Perri G, Back DJ. Boffito M, et al. Among authors: back dj. Br J Clin Pharmacol. 2002 Sep;54(3):262-8. doi: 10.1046/j.1365-2125.2002.01663.x. Br J Clin Pharmacol. 2002. PMID: 12236846 Free PMC article.

9

Simultaneous determination of rifampicin and efavirenz in plasma.

Boffito M, Tija J, Reynolds HE, Hoggard PG, Bonora S, Di Perri G, Back DJ. Boffito M, et al. Among authors: back dj. Ther Drug Monit. 2002 Oct;24(5):670-4. doi: 10.1097/00007691-200210000-00015. Ther Drug Monit. 2002. PMID: 12352941

10

Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.

Boffito M, Arnaudo I, Raiteri R, Bonora S, Sinicco A, Di Garbo A, Reynolds HE, Hoggard PG, Back DJ, Di Perri G. Boffito M, et al. Among authors: back dj. AIDS. 2002 Oct 18;16(15):2081-3. doi: 10.1097/00002030-200210180-00015. AIDS. 2002. PMID: 12370509

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

379 results

Search Page